nasal

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
nasal
Generic name
PHENYLEPHRINE HYDROCHLORIDE
Manufacturer
Walgreen Company
Product type
HUMAN OTC DRUG
SPL set ID
8db7df1c-46b5-49bd-9002-50b12d58001a
SPL ID
96a9715b-c44b-4eed-91ba-bf3c03a95ffb
Version
3
Effective date
2024-09-13
Source export date
2026-09-28
Source partition
1
Source file
https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-09-28/9c7783846d422acb0c9e59457606951c785a7d28cc631c8cc4839d0dc7c55f39/drug-label-0001-of-0014.json.zip
Source manifest SHA-256
cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run
20260929T050834Z
Imported at
2026-09-29 05:14:16
Harmonized routes table
Harmonized routes
NASAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Warnings Ask a doctor before use if you have • heart disease • diabetes • thyroid disease • high blood pressure • trouble urinating due to an enlarged prostate gland When using this product • do not use more than directed • do not use for more than 3 days. Frequent or prolonged use may cause nasal congestion to come back or get worse. • use only as directed • temporary discomfort such as burning, stinging, sneezing or an increase in nasal discharge may occur • use of this container by more than one person may spread infection Stop use and ask a doctor if symptoms persist If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. (1-800-222-1222)

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.